ÐÓ°ÉÂÛ̳

Skip to main content
Quest Diagnostics

Detection of SARS-CoV-2 IgG Targeting Nucleocapsid or Spike Protein by Four High Throughput Immunoassays Authorized for Emergency Use

Authors: Prince HE, Givens TS, Lap¨¦-Nixon M, Clarke NJ, Schwab DA, Batterman HJ, Jones RS, Meyer WA, Kapoor H, Rowland CM, Haji-Sheikhi F, Marlowe EM

Citation: J Clin Microbiol. 2020 Aug 18;JCM.01742-20. doi: 10.1128/JCM.01742-20. Online ahead of print.

Specialties:?ÐÓ°ÉÂÛ̳-19,?Dermatology,?Infectious Disease

Download key summary

Related content

Publication
SARS-CoV-2 Spike-Protein Targeted Serology Test Results and Their Association With Subsequent ÐÓ°ÉÂÛ̳-19-Related Outcomes
Publication
Comparison of SARS-CoV-2 RT-PCR Ct values across multiple assays with different targets
Test FAQ
SARS CoV 2 Antibody Testing

Our company

Quest? is the brand name used for services offered by ÐÓ°ÉÂÛ̳ and its affiliated companies. ÐÓ°ÉÂÛ̳ and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.? Other affiliates operated under the Quest? brand, such as Quest Consumer Inc., do not provide HIPAA-covered services.?

?

Quest?, Quest Diagnostics?, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks¡ª? and ?¡ªare the property of their respective owners. ? 2025 ÐÓ°ÉÂÛ̳. All rights reserved. Image content features models and is intended for illustrative purposes only.